MCID: SCR001
MIFTS: 41

Secretory Meningioma

Categories: Cancer diseases, Neuronal diseases

Aliases & Classifications for Secretory Meningioma

MalaCards integrated aliases for Secretory Meningioma:

Name: Secretory Meningioma 12 54 15 17 71
Meningioma 71

Classifications:



External Ids:

Disease Ontology 12 DOID:4588
MeSH 43 D008579
NCIt 49 C4718
SNOMED-CT 67 253081009
UMLS 71 C0025286 C1384406

Summaries for Secretory Meningioma

MalaCards based summary : Secretory Meningioma, also known as meningioma, is related to meningioma, radiation-induced and signet ring cell adenocarcinoma. An important gene associated with Secretory Meningioma is MUC1 (Mucin 1, Cell Surface Associated), and among its related pathways/superpathways is Cytoskeletal Signaling. The drugs Thrombin and Tranexamic Acid have been mentioned in the context of this disorder. Affiliated tissues include brain, bone and pituitary, and related phenotype is Increased proliferation.

Related Diseases for Secretory Meningioma

Diseases related to Secretory Meningioma via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 320)
# Related Disease Score Top Affiliating Genes
1 meningioma, radiation-induced 30.4 VIM SMARCB1 NF2 MUC1
2 signet ring cell adenocarcinoma 29.9 MUC1 KRT7 CEACAM5
3 spinal meningioma 29.9 TRAF7 SMARCE1 SMARCB1 NF2
4 meningothelial meningioma 29.5 TRAF7 SMARCE1 SERPINA3 NF2
5 meningioma, familial 29.1 TRAF7 SMARCE1 SMARCB1 SERPINA3 NF2 KLF4
6 lymphoplasmacyte-rich meningioma 10.7
7 perineurioma 10.5 VIM MUC1
8 papillary tumor of the pineal region 10.5 VIM MUC1
9 endometrial mucinous adenocarcinoma 10.5 VIM MUC1
10 scrotum paget's disease 10.5 MUC1 KRT7
11 gallbladder signet ring cell adenocarcinoma 10.5 MUC1 KRT7
12 cutaneous leiomyosarcoma 10.5 VIM MUC1
13 middle ear adenoma 10.4 MUC1 KRT7
14 reticulum cell sarcoma 10.4 VIM MUC1
15 extraskeletal ewing sarcoma 10.4 VIM MUC1
16 desmoplastic small round cell tumor 10.4 VIM MUC1
17 pericardial mesothelioma 10.4 VIM MUC1
18 benign metastasizing leiomyoma 10.4 VIM KRT7
19 glandular cystitis 10.4 MUC1 KRT7
20 clear cell ependymoma 10.4 VIM MUC1
21 cystadenofibroma 10.4 MUC1 KRT7
22 ossifying fibromyxoid tumor 10.4 VIM MUC1
23 solid adenocarcinoma with mucin production 10.4 MUC1 KRT7
24 polymorphous low-grade adenocarcinoma 10.4 VIM MUC1
25 biphasic synovial sarcoma 10.4 VIM MUC1
26 mucinous tubular and spindle renal cell carcinoma 10.4 MUC1 KRT7
27 brain edema 10.4
28 endosalpingiosis 10.4 MUC1 KRT7
29 ovarian serous cystadenofibroma 10.4 MUC1 KRT7
30 mixed fibrolamellar hepatocellular carcinoma 10.4 MUC1 KRT7
31 dendritic cell tumor 10.4 VIM MUC1
32 intravascular papillary endothelial hyperplasia 10.4 VIM SERPINA3
33 renal pelvis carcinoma 10.4 KRT7 CEACAM7
34 malignant peritoneal mesothelioma 10.4 NF2 MUC1
35 congenital epulis 10.4 VIM SERPINA3
36 nephrogenic adenoma 10.4 MUC1 KRT7
37 epulis 10.4 VIM SERPINA3
38 syringocystadenoma papilliferum 10.4 SERPINA3 MUC1
39 granulosa cell tumor of the ovary 10.3 VIM KRT7
40 multicentric reticulohistiocytosis 10.3 VIM SERPINA3
41 adenomyoma 10.3 MUC1 KRT7
42 odontogenic myxoma 10.3 VIM SERPINA3
43 gastric squamous cell carcinoma 10.3 SERPINA3 KRT7
44 vulvar eccrine porocarcinoma 10.3 MUC1 CEACAM5
45 lipid-rich breast carcinoma 10.3 MUC1 CEACAM5
46 astroblastoma 10.3 VIM MUC1
47 embryonal sarcoma 10.3 VIM SERPINA3
48 osteofibrous dysplasia 10.3 VIM MUC1
49 sclerosing hemangioma 10.3 MUC1 KRT7
50 pediatric meningioma 10.3 TRAF7 NF2

Graphical network of the top 20 diseases related to Secretory Meningioma:



Diseases related to Secretory Meningioma

Symptoms & Phenotypes for Secretory Meningioma

GenomeRNAi Phenotypes related to Secretory Meningioma according to GeneCards Suite gene sharing:

26
# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Increased proliferation GR00094-A 8.62 NF2 SMARCB1

Drugs & Therapeutics for Secretory Meningioma

Drugs for Secretory Meningioma (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 242)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Thrombin Approved, Investigational Phase 4
2
Tranexamic Acid Approved Phase 4 1197-18-8 5526
3 Fibrin Tissue Adhesive Phase 4
4 Hemostatics Phase 4
5 Coagulants Phase 4
6 Antifibrinolytic Agents Phase 4
7
Cisatracurium Approved Phase 3 96946-41-7
8
Propofol Approved, Investigational, Vet_approved Phase 3 2078-54-8 4943
9
Magnesium Sulfate Approved, Investigational, Vet_approved Phase 3 7487-88-9 24083
10
Sevoflurane Approved, Vet_approved Phase 3 28523-86-6 5206
11
Progesterone Approved, Vet_approved Phase 3 57-83-0 5994
12
Fentanyl Approved, Illicit, Investigational, Vet_approved Phase 3 437-38-7 3345
13
Donepezil Approved Phase 3 120014-06-4 3152
14
Cisplatin Approved Phase 3 15663-27-1 2767 441203 84093
15
Ondansetron Approved Phase 3 99614-02-5 4595
16
Granisetron Approved, Investigational Phase 3 109889-09-0 3510
17
Aminolevulinic acid Approved Phase 3 106-60-5 137
18
Methylphenidate Approved, Investigational Phase 3 113-45-1 4158
19
Dopamine Approved Phase 3 51-61-6, 62-31-7 681
20
Histamine Approved, Investigational Phase 3 51-45-6 774
21
Cyproheptadine Approved Phase 3 129-03-3 2913
22 Pancreatic Polypeptide Investigational Phase 3 59763-91-6
23 Antihypertensive Agents Phase 3
24 Progestins Phase 3
25 Cholinesterase Inhibitors Phase 3
26 Cholinergic Agents Phase 3
27 Analgesics Phase 3
28 Liver Extracts Phase 3
29 Cola Phase 3
30 Emetics Phase 3
31 Narcotics Phase 3
32 Analgesics, Opioid Phase 3
33 Anesthetics, General Phase 3
34 Anesthetics, Intravenous Phase 3
35 Anesthetics Phase 2, Phase 3
36 Gastrointestinal Agents Phase 3
37 Neurotransmitter Agents Phase 3
38 Central Nervous System Stimulants Phase 3
39 Dermatologic Agents Phase 3
40 Dopamine Agents Phase 3
41 Dexmethylphenidate Hydrochloride Phase 3
42 Histamine Antagonists Phase 3
43 Anti-Allergic Agents Phase 3
44
Histamine Phosphate Phase 3 51-74-1 65513
45 Histamine H1 Antagonists Phase 3
46
Serotonin Investigational, Nutraceutical Phase 3 50-67-9 5202
47
Trabectedin Approved, Investigational Phase 2 114899-77-3 108150
48
Hydroxyurea Approved Phase 2 127-07-1 3657
49
Gefitinib Approved, Investigational Phase 2 184475-35-2 123631
50
Sunitinib Approved, Investigational Phase 2 557795-19-4, 341031-54-7 5329102

Interventional clinical trials:

(show top 50) (show all 212)
# Name Status NCT ID Phase Drugs
1 Neurocognitive Outcome Assessment in Patients With Peri-optic Meningiomas After Excision With Or Without Pealing Of The Outer Layer Of The Cavernous Sinus: A Randomized Controlled Single Blinded Trial. Unknown status NCT03190122 Phase 4
2 Dissection of the Outer Layer of the Lateral Wall of the Cavernous Sinus Decreases Bleeding as Compared to Direct Tumor Attack in Middle Fossa Meningiomas: A Randomized Controlled Trial Unknown status NCT02863484 Phase 4
3 A Prospective, Randomized, Controlled Phase IV Study to Compare Bioseal Versus Standard of Care as an Adjunct to Hemostasis in Elective Brain Tumor Surgery Completed NCT02034799 Phase 4
4 Effect of Tranexamic Acid Infusion to Reduce Intraoperative Blood Loss in Large Meningioma: A Prospective Randomized Double-blind Control Study Not yet recruiting NCT04386642 Phase 4 Tranexamic acid;Placebo
5 The Effect of Magnesium Sulphate on Intraoperative Blood Loss in Meningioma Patient Undergoing Craniotomy With Tumor Removal Unknown status NCT03558516 Phase 3 Magnesium group;Normal saline group
6 PHASE 3 STUDY OF EFFICACY OF TRANEXAMIC ACID IN BRAIN TUMORS RESECTIONS Unknown status NCT01655927 Phase 3 Tranexamic Acid;Placebo: Saline
7 Efficacy of Stereotactic Conformal Radiotherapy (SCRT) Compared to Conventional Radiotherapy in Minimising Late Sequelae in Children and Young Adults With Brain Tumours: a Randomised Clinical Trial Unknown status NCT00517959 Phase 3
8 Double Blind Randomized Trial of the Anti-Progestational Agent Mifepristone In The Treatment of Unresectable Meningioma Completed NCT03015701 Phase 3 Mifepristone
9 Phase III Double Blind, Placebo Controlled Study of Donepezil in the Irradiated Brain Completed NCT00369785 Phase 3 donepezil hydrochloride;Placebo
10 Prospective Study Of Patients With Recurrent Or Incomplete Excised Benign Intercranial Meningiomas For The Evaluation Of Treatment Result With Combined Proton And Photon Irradiation To Doses 55.8 Or 63.0 CGE Completed NCT02947984 Phase 3
11 Randomized Controlled Trial of Acupressure to Control Chemotherapy-Induced Nausea (CIN) in Children Receiving Highly Emetogenic Chemotherapy Completed NCT01346267 Phase 3
12 A Randomized, Double-blind, Placebo-controlled Multi-center Study to Evaluate the Safety and Efficacy of Fentanyl Sublingual Spray (Fentanyl SL Spray) for the Treatment of Breakthrough Cancer Pain Completed NCT00538850 Phase 3 Fentanyl sublingual spray;Placebo
13 Phase III Trial of Observation Versus Irradiation for a Gross Totally Resected Grade II Meningioma Recruiting NCT03180268 Phase 3
14 The Role of Optic Nerve Sheath Fenestration in Leukemic Patients Having Increased Intracranial Pressure Active, not recruiting NCT04431882 Phase 2, Phase 3
15 A Phase 3 Multicenter Study of Gleolan (Aminolevulinic Acid Hydrochloride) to Enhance Visualization of Tumor in Patients With Newly Diagnosed or Recurrent Meningiomas Not yet recruiting NCT04305470 Phase 3 Gleolan (Aminolevulinic Acid Hydrochloride)
16 Observation Versus Conventional-Fractionated Radiotherapy or Radiosurgery After Non-radical Surgery for Benign Intracranial Meningiomas: A Phase III Study Terminated NCT00104936 Phase 3
17 A Phase III, Double-Blind, Prospective Randomized Clinical Trial of the Effect of D-threo-methylphenidate HCl (d-MPH) on Quality of Life in Brain Tumor Patients Receiving Radiation Therapy Terminated NCT00031798 Phase 3 methylphenidate hydrochloride
18 Prevention of Cancer/Treatment-Related Weight Loss in Children at High Nutritional Risk Terminated NCT01132547 Phase 3 cyproheptadine hydrochloride
19 Phase II Study of Hydroxyurea for the Treatment of Recurrent and/or Nonoperable Meningioma Unknown status NCT00006119 Phase 2 hydroxyurea
20 IMATINIB Plus Hydroxyurea in the Treatment of Recurrent or Progressive Meningiomas: a Randomized Phase II Study Unknown status NCT00904735 Phase 2 hydroxyurea;imatinib mesylate
21 Combination of Everolimus and Octreotide LAR in Aggressive Recurrent Meningiomas. Unknown status NCT02333565 Phase 2 Everolimus;Octreotide
22 Trabectedin for Recurrent Grade II or III Meningioma: a Randomized Phase II Study of the EORTC Brain Tumor Group Completed NCT02234050 Phase 2 Trabectedin
23 Phase II Study of Hydroxyurea for Unresectable Meningioma Completed NCT00003590 Phase 2 hydroxyurea
24 A Phase II Trial of PTK-787 in Recurrent or Progressive Meningiomas Completed NCT00348790 Phase 2 vatalanib
25 Phase II Study of Monthly SOM230C for Recurrent or Progressive Meningioma Completed NCT00859040 Phase 2 SOM230C
26 Adjuvant Postoperative High-Dose Radiotherapy for Atypical and Malignant Meningioma: a Phase-II and Observation Study Completed NCT00626730 Phase 2
27 ZD1839 FOR Treatment Of Recurrent Or Progressive Malignant Astrocytoma Or Glioblastoma And Recurrent Or Progressive Meningioma: A Phase II Study With A Phase I Component For Patients Receiving EIAEDs Completed NCT00025675 Phase 2 gefitinib
28 A Phase II Study of Imatinib Mesylate Plus Hydroxyurea in the Treatment of Patients With Recurrent/Progressive Meningioma Completed NCT00354913 Phase 2 hydroxyurea;imatinib mesylate
29 Phase II Trial of Sunitinib (SU011248) in Patients With Recurrent or Inoperable Meningioma Completed NCT00589784 Phase 2 Sunitinib
30 Phase II Trial of STI571 (NSC 716051) in Patients With Recurrent Meningioma Completed NCT00045734 Phase 2 imatinib mesylate
31 Peptide Receptor Radionuclide Therapy Administered to Participants With Meningioma With 67Cu-SARTATE™: A Single-centre, Open-label, Non- Randomised, Phase I-IIa Theranostic Clinical Trial Completed NCT03936426 Phase 1, Phase 2 Cu-64 SARTATE and Cu-67 SARTATE
32 A Feasibility Study of Armodafinil for Brain Radiation-Induced Fatigue Completed NCT01032200 Phase 2 Armodafinil
33 Phase I/II Trial of STI571 (NSC 716051) in Patients With Recurrent Malignant Gliomas Completed NCT00010049 Phase 1, Phase 2 imatinib mesylate
34 Levetiracetam and Pregabalin for Monotherapy in Patients With Brain Tumors and Seizures. A Phase II Randomized Study. Completed NCT00629889 Phase 2 levetiracetam;pregabalin
35 A Phase I/II Trial of OSI-774 in Patients With Recurrent Malignant Gliomas and Malignant Gliomas Post Radiation Therapy Completed NCT00045110 Phase 1, Phase 2 erlotinib hydrochloride
36 A Phase II Trial of Rebeccamycin Analogue (NSC #655649) in Children With Solid Tumors Completed NCT00006102 Phase 2 becatecarin
37 Phase II Treatment of Children With Newly Diagnosed Malignant Central Nervous System Tumors With Temozolomide Prior to Radiation Therapy Completed NCT00005955 Phase 2 temozolomide
38 A Randomized Phase II Trial of Bevacizumab to Control Brain Radiation Damage Completed NCT00492089 Phase 2 bevacizumab;placebo
39 A Phase I/II Trial of SU5416 in Patients With Recurrent High Grade Astrocytomas or Mixed Gliomas Completed NCT00004868 Phase 1, Phase 2 semaxanib
40 Phase I Study of At-Labeled Anti-Tenascin Human/Mouse Chimeric Monoclonal Antibody 81C6 (ch81C6) Via Surgically Created Cystic Resection Cavity in the Treatment of Patients With Primary or Metastatic Brain Tumors Completed NCT00003461 Phase 1, Phase 2
41 Donepezil and EGb761 in Improving Neurocognitive Function in Patients Who Have Previously Undergone Radiation Therapy for Primary Brain Tumor or Brain Metastases Completed NCT00070161 Phase 2 donepezil hydrochloride
42 Phase II Trial of Irinotecan in Children With Refractory Solid Tumors Completed NCT00004078 Phase 2 irinotecan hydrochloride
43 Phase II Study to Evaluate the Efficacy of Recombinant Interferon-Alpha in the Treatment of Recurrent Unresectable Meningiomas and Malignant Meningiomas Completed NCT00002965 Phase 2
44 Phase II Trial Of High Dose Cyclophosphamide, Cisplatin And Carmustine With Stem Cell Reconstitution Followed By Specific Cellular Therapy In Patients With Recurrent Or Refractory Brain Tumors Completed NCT00014573 Phase 2 carmustine;cisplatin;cyclophosphamide;paclitaxel
45 Proton Radiation for Low Grade Gliomas Completed NCT01024907 Phase 1, Phase 2
46 Combination of Hydroxyurea and Verapamil for Refractory Meningiomas Completed NCT00706810 Phase 2 Hydroxyurea;Verapamil
47 Phase II Study of Metastatic Cancer That Expresses NY-ESO-1 Using Lymphodepleting Conditioning Followed by Infusion of Anti-NY ESO-1 Murine TCR-Gene Engineered Lymphocytes Completed NCT01967823 Phase 2 Cyclophosphamide;Fludarabine;Aldesleukin
48 Phase II Trial of Pembrolizumab in Recurrent or Residual High Grade Meningioma Recruiting NCT03279692 Phase 2 Pembrolizumab
49 A Single Arm, Open-label, Multicenter Phase II Study of 177Lu-DOTATATE Radionuclide in Adults With Progressive or High-risk Meningioma Recruiting NCT03971461 Phase 2 Lutathera
50 An Open-Label Phase II Study of Nivolumab in Adult Participants With Recurrent High-Grade Meningioma Recruiting NCT02648997 Phase 2 Nivolumab - 240 mg;Ipilimumab - 3 mg/kg;Nivolumab - 480 mg;Nivolumab - 1 mg/kg

Search NIH Clinical Center for Secretory Meningioma

Genetic Tests for Secretory Meningioma

Anatomical Context for Secretory Meningioma

MalaCards organs/tissues related to Secretory Meningioma:

40
Brain, Bone, Pituitary, Spinal Cord, Breast, Lung, Pineal

Publications for Secretory Meningioma

Articles related to Secretory Meningioma:

(show top 50) (show all 14299)
# Title Authors PMID Year
1
[A rare case of tumor-to-tumor metastasis: secondary deposits of pulmonary adenocarcinoma in a secretory meningioma]. 61 54
12368922 2002
2
Pseudopsammomatous meningioma with elevated serum carcinoembryonic antigen: a true secretory meningioma. Case report. 61 54
1984492 1991
3
Circumpapillary collateral vessel development in iatrogenic central retinal artery occlusion observed using OCT angiography. 61
32490281 2020
4
Combined neurosurgical and orbital intervention for spheno-orbital meningiomas - the Manchester experience. 61
31658848 2020
5
Apatinib in recurrent anaplastic meningioma: a retrospective case series and systematic literature review. 61
32212907 2020
6
Ganoderic acid A/DM-induced NDRG2 over-expression suppresses high-grade meningioma growth. 61
31732915 2020
7
Exposure to lead increases the risk of meningioma and brain cancer: A meta-analysis. 61
32146339 2020
8
Simulating Episode-Based Bundled Payments for Cranial Neurosurgical Procedures. 61
31515558 2020
9
Prognostic Value of Histopathological Features and Loss of H3K27me3 Immunolabeling in Anaplastic Meningioma: A Multicenter Retrospective Study. 61
32447376 2020
10
Continuous progression of hemorrhage of sphenoid ridge meningioma causing cerebral hernia: A case report and literature review. 61
32566005 2020
11
Low recurrence after Simpson grade II resection of spinal benign meningiomas in a single-institute 10-year retrospective study. 61
32360158 2020
12
Intraventricular microcystic meningioma in a child: a case report. 61
31848722 2020
13
Socioeconomic burden and quality of life in meningioma patients. 61
32128657 2020
14
Functional outcome after surgical treatment of spinal meningioma. 61
32409209 2020
15
Glioblastoma multiforme that unusually present with radiographic dural tails: Questioning the diagnostic paradigm with a rare case report. 61
32489510 2020
16
HbA1c in patients with intracranial meningiomas WHO grades I and II: A preliminary study. 61
32134566 2020
17
Evaluation of Epidemiologic Factors, Radiographic Features, and Pathologic Findings for Predicting Peritumoral Brain Edema in Meningiomas. 61
31922353 2020
18
Clinical features of newly developed NF2 intracranial meningiomas through comparative analysis of pediatric and adult patients. 61
32229353 2020
19
Frequent inactivating mutations of the PBAF complex gene PBRM1 in meningioma with papillary features. 61
32405805 2020
20
Extradural Devascularization for Resection of a Lesser Sphenoid Wing Meningioma: 2-Dimensional Operative Video. 61
31552415 2020
21
Posterior Cranial Fossa Meningioma Presenting With Hearing Impairment and Recurrent Vertigo. 61
31132901 2020
22
Germline mutations in MEN1 are associated with the tumorigenesis of pituitary adenoma associated with meningioma. 61
32565981 2020
23
In vivo imaging of cell proliferation in meningioma using 3'-deoxy-3'-[18F]fluorothymidine PET/MRI. 61
32047966 2020
24
In Vitro Effect of Dovitinib (TKI258), a Multi-Target Angiokinase Inhibitor on Aggressive Meningioma Cells. 61
32441531 2020
25
Ossified anterior foramen magnum meningioma: report of long-term surgical outcome. 61
32526364 2020
26
Patient-Derived Orthotopic Xenograft (PDOX) Mouse Models of Primary and Recurrent Meningioma. 61
32517016 2020
27
Anaplastic meningioma seeding of the abdominal wall following calvarial bone flap preservation. 61
32382362 2020
28
Predictors of pre-operative cognitive impairment in meningioma patients over 60 years old. 61
32493294 2020
29
Meningioma with rhabdoid features combined with meningioangiomatosis in infancy: a novel combination. 61
31897634 2020
30
Anterior Transpetrosal Approach and Microsurgical Resection of a Petrous Tentorial Meningioma: 3-Dimensional Operative Video. 61
31504886 2020
31
A clinical study of ocular motor nerve functions after petroclival meningioma resection. 61
32100111 2020
32
Surgical nuances of the expanded endoscopic anterior skull base craniectomy for hyperostotic meningioma resection. 61
32172440 2020
33
Incidence and predictors of kyphotic deformity following resection of cervical intradural tumors in adults: a population-based cohort study. 61
32556521 2020
34
Effective drug treatment identified by in vivo screening in a transplantable patient-derived xenograft model of chronic myelomonocytic leukemia. 61
32576961 2020
35
Anatomical Variations in the Location of Veins Draining Into the Anterior Superior Sagittal Sinus: Implications for the Transbasal Approach. 61
31748805 2020
36
Brain tumor classification using modified local binary patterns (LBP) feature extraction methods. 61
32234609 2020
37
A practical predictor of the growth potential of benign meningiomas: Hypointensity of surface layer in T2-weighted magnetic resonance imaging. 61
32018148 2020
38
Landscape of immune cell gene expression is unique in predominantly WHO grade 1 skull base meningiomas when compared to convexity. 61
32493984 2020
39
Differentiation Between Benign and Nonbenign Meningiomas by Using Texture Analysis From Multiparametric MRI. 61
31710413 2020
40
Intravenous sinus meningioma with intraluminal extension to the internal jugular vein: case report and review of the literature. 61
32536219 2020
41
Small Cell Variant of Anaplastic Lymphoma Kinase-Positive Anaplastic Large Cell Lymphoma of the Dura Mimicking Tentorial Meningioma. 61
32151774 2020
42
Extracranial meningioma as an incidental infratemporal fossa mass in a patient presenting with a history of traumatic brain injury. 61
32554455 2020
43
Commentary: Stereotactic Radiosurgery for Intracranial Noncavernous Sinus Benign Meningioma: International Stereotactic Radiosurgery Society Systematic Review, Meta-Analysis and Practice Guideline. 61
32570276 2020
44
When a benign disease turns into disaster: a unique case of a surgically treated hemorrhagic sylvian fissure meningioma. 61
30942054 2020
45
Smell Preservation following Unilateral Endoscopic Transnasal Approach to Resection of Olfactory Groove Meningioma: A Multi-institutional Experience. 61
32500000 2020
46
Differentiation of intracranial meningioma from dural metastasis with somatostatin receptor scintigraphy: An underutilised solution to a common problem. 61
31995193 2020
47
Multiple Whole Chromosomal Gains Define Angiomatous Meningiomas and Are Absent From the Tumor Vasculature. 61
32357369 2020
48
Treatment Outcomes of Incidental Intracranial Meningiomas: Results from the IMPACT Cohort. 61
32200011 2020
49
[68Ga]Ga-DOTA-TOC PET/CT fused to MRI in post-operative evaluation of olfactory groove meningioma: a case on millimetric remnants. 61
32556482 2020
50
Association of Race with Survival in Intracranial World Health Organization Grade II and III Meningioma in the United States: Systematic Literature Review. 61
32142947 2020

Variations for Secretory Meningioma

Expression for Secretory Meningioma

Search GEO for disease gene expression data for Secretory Meningioma.

Pathways for Secretory Meningioma

Pathways related to Secretory Meningioma according to GeneCards Suite gene sharing:

# Super pathways Score Top Affiliating Genes
1 11.41 VIM NF2 MUC1 KRT7

GO Terms for Secretory Meningioma

Cellular components related to Secretory Meningioma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 SWI/SNF complex GO:0016514 9.16 SMARCE1 SMARCB1
2 nBAF complex GO:0071565 8.96 SMARCE1 SMARCB1
3 npBAF complex GO:0071564 8.62 SMARCE1 SMARCB1

Biological processes related to Secretory Meningioma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 nucleosome disassembly GO:0006337 8.96 SMARCE1 SMARCB1
2 positive regulation of histone H4 acetylation GO:0090240 8.62 SMARCB1 MUC1

Sources for Secretory Meningioma

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
28 GO
29 GTR
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 LOVD
41 MedGen
43 MeSH
44 MESH via Orphanet
45 MGI
48 NCI
49 NCIt
50 NDF-RT
53 NINDS
54 Novoseek
56 OMIM
57 OMIM via Orphanet
61 PubMed
63 QIAGEN
68 SNOMED-CT via HPO
69 TGDB
70 Tocris
71 UMLS
72 UMLS via Orphanet
Content
Loading form....